Inhibition effect of oxyepiberberine isolated from Coptis chinensis franch. On non-small cell lung cancer based on a network pharmacology approach and experimental validation

• Published in: Journal of ethnopharmacology Vol. 278; p. 114267
• Main Authors: Zhang, Ying, Yao, Yunfeng, Fu, Yingjie, Yuan, Zixin, Wu, Xingpan, Wang, Tianshun, Hong, Zongchao, Yang, Yanfang, Wu, Hezhen
• Format: Journal Article
• Language: English
• Published: Elsevier B.V 05.10.2021
• Subjects: Biological experimental; Cell proliferation; Coptis chinensis (Huanglian); Network pharmacology; NSCLC; Oxyepiberberine; Cell proliferation; OPB; NSCLC; HL; HSP; DMSO; ESR; ESI/MS; MAPK; FAK; MMP; NMR; FBS; Coptis chinensis (Huanglian); Network pharmacology; Biological experimental; Oxyepiberberine; TCM; ERK
• ISSN: 0378-8741; 1872-7573
• DOI: 10.1016/j.jep.2021.114267

As an important Chinese herb, Coptis chinensis Franch. (Huanglian, HL) has a long history of usage for clearing heat, eliminating dampness, purging fire and detoxification in Traditional Chinese Medicine (TCM). HL, also called goldthread, was frequently used for the treatment of typhoid, tuberculosis, epidemic cerebrospinal meningitis, pertussis, and other lung-related diseases. Modern research has shown that HL and its main compounds also have anti-tumor effects. However, studies have not reported whether its main compounds inhibit Non-small cell lung cancer (NSCLC) development and progression. This study aimed to find out the potential targets and mechanisms of Oxyepiberberine (OPB) isolated from HL in the treatment of NSCLC, using network pharmacology and biological experimental. Silica gel chromatography column was used to isolate OPB from HL, and the structure of OPB was elucidated using different spectroscopic analysis methods, including 1H-nuclear magnetic resonance (NMR), 13C-NMR and electrospray ionization mass spectrometry (ESI/MS). MTT assay was performed to determine cell proliferation of OPB on A549, H1975 and BEAS-2B cells. Then, the potential targets, pathways and hub genes of OPB for treating NSCLC were screened out through network pharmacology. Based on the results of network pharmacology, core targets of OPB for treating NSCLC were docking with OPB via molecular docking. Wound healing, plate clone, Hoechst staining, and western blot assay were used to verify the function of OPB in treatment of NSCLC. OPB was isolated from the HL, its molecular formula was identified as C20H17NO5. Through MTT, OPB significantly inhibited the proliferation of H1975 cells and A549 cells, and A549 was chosen as the test cancer cell. Through network pharmacology, 22 potential targets, 156 related-pathways, and 6 hub genes were screened out. The results of molecular docking showed that SRC, BRAF, and MMP9 were the core targets of OPB against NSCLC. Through biological experimental, it was found that OPB inhibited growth and migration of A549 cells. In addition, OPB induced apoptosis in A549 cells. Through western blot assay, the expressions of Src, ERK1/2 and other four proteins were down-regulated, which suggested that OPB inhibited the proliferation of lung cancer cells by down-regulating SRC-FAK-RAS-RAF-MEK-ERK pathway, so as to achieve the anti-NSCLC effect. Our study demonstrated that anti-NSCLC effect of OPB through network and experiments, which provided a theoretical basis for the clinical antitumor of OPB, and provided a foundation for further study of OPB. [Display omitted] •This study is the first to study the anti-non-small cell lung cancer effect of Oxyepiberberine (OPB) using network pharmacology combined with experimental method.•We isolated OPB from HL, and identified its structure through MS and NMR.•OPB inhibits the A549 cells through apoptosis-promoting and inhibits the migration of A549 cells.•Src, BRAF, and MMPs are as key proteins of OPB against non-small cell lung cancer identified by network pharmacology method.•Through experimental methods, we demonstrated that the mechanism of action of OPB is to regulate SRC/FAK/RAS/RAF/MEK/ERK pathway.